AVROBIO, Inc AVRO

CryptoFundManager Premium

Want to buy a stock at all time low? On 1/5/2022 Barclays Boosted the Price Target for AVROBIO, Inc. (AVRO) from Overweight to Overweight and the price target from $6.00 to $22.00. Now AVRO is $1.34. The next important resistance at $3.80.

CryptoFundManager Premium

AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide. AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04. 73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company. JPMorgan Chase and BlackRock Inc. have...

Swing_Trading_as_a_BUSINESS Pro

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company manufactures products include AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis. If...

plugportal

$AVRO Scanner >> [ ] || Reason >> Wedbush adjusts AVROBIO's price target to $40.00 from $36.00 || Reason >> Price looks to be bottoming. || Reason >>Blue Candle BUY signal issued || Watch >>Trend is still bearish. || Watch >> >> Momentum >> Rising >> Near Term >> Rising >> Intermediate >> Falling || Watch >> Broke...

Veets11 Pro+

massive support at 12. looks like a great r/r swing trade or hold for a potential break out over 30 $XBI

Lextrading Pro

Get in BELOW the secondary offering at $15.

Lextrading Pro

More positive clinical validates their platform. Assets further de-risked.

Lextrading Pro

Ride the wave.

Lextrading Pro

Looking to open a position at 12.80 at the 78.6 line

AlTorress

Tickeron AI shows that a buy signal is indicated by this change in price, due to the trend repositioning higher. In 2 of 2 cases where AVRO's 50-day Moving Average crossed above its 200-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 90%.

ProjectSyndicate Premium

Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates AVRO 4H chart: BUY/HOLD 60% gains(NEW) 🔸 Summary and potential...

ProjectSyndicate Premium

before we kick start the update. your upvotes/subs are appreciated. Why get subbed to to me on Tradingview? -15+ years real live trading experience -TOP Author on TradingView -professional chart break downs -key levels -no junk on my charts -frequent updates -covering FX/crypto/US stocks -24/7 uptime so constant updates So without further due. Keep it...

dobisa Premium Updated 

This looks like standard consolidation after a big move. It might even continue.

uriyah

AVRO LONG Potential

ChristopherCarrollSmith

AVROBIO got a good pop today from very positive Phase 2 clinical trial results from its kidney drug. Unquestionably the news was good; the drug shows strong efficacy and no adverse events. However, this was only a Phase 2 trial so there's a long way still to go in the approval process. Meanwhile, the company is losing money and is rated as an overvalued and...

Torune

Nice move first tradingview analysis follow me